Xiaodan Wei
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Pharmacology top 2%
- Pharmacology and Obesity Treatment
Papers in
-
- Nanoplatforms for cancer theranostics 22
-
- Extracellular vesicles in disease 5
- Co-authors
- Aldo P. Maggioni (2 shared papers)Hertzel C. Gerstein (2 shared papers)Rafael Díaz (2 shared papers)Jean‐Claude Tardif (2 shared papers)Eldrin F. Lewis (2 shared papers)Scott D. Solomon (2 shared papers)Lars Køber (2 shared papers)Francesca Lawson (2 shared papers)
- Journals
- Oncotarget (4 papers)Scientific Reports (2 papers)Advanced Healthcare Materials (2 papers)Acta Biomaterialia (2 papers)ACS Materials Letters (2 papers)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Xiaodan Wei
50 papers receiving 2.5k citations
Xiaodan Wei's Hit Papers
Peers
Comparison fields: 5 of 130
- Endocrinology, Diabetes and Metabolism 1.7k
- Pharmacology 356
- Cardiology and Cardiovascular Medicine 311
- Molecular Biology 914
- Surgery 569
Countries citing papers authored by Xiaodan Wei
This map shows the geographic impact of Xiaodan Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaodan Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaodan Wei more than expected).
Fields of papers citing papers by Xiaodan Wei
This network shows the impact of papers produced by Xiaodan Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaodan Wei. The network helps show where Xiaodan Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaodan Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Hit paper breakdown → | 2015 | 1726 |
| 2 | 2015 | 66 | |
| 3 | 2021 | 56 | |
| 4 | 2015 | 56 | |
| 5 | 2021 | 51 | |
| 6 | 2022 | 50 | |
| 7 | 2024 | 41 | |
| 8 | 2022 | 38 | |
| 9 | 2015 | 29 | |
| 10 | 2021 | 28 | |
| 11 | 2021 | 28 | |
| 12 | 2015 | 27 | |
| 13 | 2023 | 25 | |
| 14 | 2020 | 25 | |
| 15 | 2018 | 24 | |
| 16 | 2022 | 24 | |
| 17 | 2023 | 22 | |
| 18 | 2021 | 21 | |
| 19 | 2017 | 21 | |
| 20 | 2016 | 19 |
About Xiaodan Wei
Xiaodan Wei is a scholar working on Biomedical Engineering, Molecular Biology, Materials Chemistry, Pulmonary and Respiratory Medicine and Oncology, having authored 53 papers that have together received 2.6k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (22 papers), Nanoparticle-Based Drug Delivery (6 papers), Photodynamic Therapy Research Studies (5 papers), Extracellular vesicles in disease (5 papers), Immune cells in cancer (4 papers), Advanced Nanomaterials in Catalysis (4 papers), Cancer, Lipids, and Metabolism (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.7k citations), Pharmacology (356 citations), Cardiology and Cardiovascular Medicine (311 citations), Molecular Biology (914 citations) and Surgery (569 citations). Xiaodan Wei has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Aldo P. Maggioni, Hertzel C. Gerstein, Rafael Díaz, Jean‐Claude Tardif, Eldrin F. Lewis, Scott D. Solomon, Lars Køber, Francesca Lawson, Kenneth Dickstein and Jeffrey L. Probstfield. Their work appears in journals such as Oncotarget, Scientific Reports, Advanced Healthcare Materials, Acta Biomaterialia and ACS Materials Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.